Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration

Molecular Aspects of Medicine

Volumn 18, Issue SUPPL., 1997, Pages 299-305

  Sinatra, Stephen T ^a,b  

^a Manchester Hospital   (United States)

^b School of Medicine   (United States)

Author keywords

Bioavailability of coenzyme Q10; Cardiomyopathy (idiopathic); Coenzyme Q10 (ubiquinone); Congestive heart failure; HMG co reductase inhibitors; Serum assay of CoQ10

Indexed keywords

UBIDECARENONE;

AGED; CARDIOMYOPATHY; CASE REPORT; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; FEMALE; HUMAN; QUALITY OF LIFE;

EID: 0030868091     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0098-2997(97)00011-3     Document Type: Conference Paper

References (10)

1. 10 levels in humans. Proceedings of the National Academy of Science USA, 87, 8931-8934.
2. 10-Proceedings of the National Academy of Science USA, 82, 901-904.
3. 10 for cardiomyopathy. Klin-Wochenschr, 66, 13 583-590.
4. 10 therapy for idiopathic dilated cardiomyopathy. American Journal of Cardiology, 65, 521-533.
5. 10 in human heart disease. Part II. International Journal of Vitamin Research, 42, 413-434.
6. Lucker, P. W., Wetzelsberger, N., Hennings, G., and Rehn, D. (1984). Pharmacokinetics of coenzyme ubidecarenone in healthy volunteers. Biomedical and Clinical Aspects of Coenzyme Q, (K. Folkers and Y. Yamamura, eds), Vol 4, pp. 143-151. Elsevier, Amsterdam.
7. 10 therapy in patients with congestive heart failure. Clinical Investigations, 71, S134-S136.
8. 10-containing formulations. Unpublished Manuscript. New York Medical College.
9. 10) in the long-term treatment of idiopathic dilated cardiomyopathy. European Heart Journal, 13, 1528-1533.
10. Rauchova, H., Drahota, Z. and Lenaz, G. (1995). Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiology Research, 44, 209-216.